A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer

BACKGROUND: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line chemotherapy. METHODS: In this single-center, open-label, dose-escalating phase I trial, p...

全面介紹

Na minha lista:
書目詳細資料
發表在:Chin J Cancer Res
Main Authors: Zhao, Jun, Zhuo, Minglei, Wang, Zhijie, Duan, Jianchun, Wang, Yuyan, Wang, Shuhang, An, Tongtong, Wu, Meina, Wang, Jie
格式: Artigo
語言:Inglês
出版: AME Publishing Company 2016
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4779759/
https://ncbi.nlm.nih.gov/pubmed/27041923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2016.02.07
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍